Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide in Metastatic Breast Cancer
NCT04103853Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Sep 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of proxalutamide in breast cancer, sponsored by Kintor Pharmaceutical Limited. Primary endpoints: Dose-limiting Toxicity at 35 days, Maximum Tolerated Dose at 35 days and 1 more. Started Sep 2017; status: completed.
02
Drugs
proxalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04103853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103853.